Graft-versus-host driven graft-versus-leukemia effect of minor histocompatibility antigen HA-1 in chronic myeloid leukemia patients
T Mutis, R Brand, D Gallardo, A Van Biezen… - Leukemia, 2010 - nature.com
T Mutis, R Brand, D Gallardo, A Van Biezen, D Niederwieser, E Goulmy
Leukemia, 2010•nature.com1 Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA et al. Adverse
prognostic significance of KIT mutations in adult acute myeloid leukemia with inv (16) and t
(8; 21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 3904–3911. 2
Marcucci G, Caligiuri MA, Dohner H, Archer KJ, Schlenk RF, Dohner K et al. Quantification of
CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV (16) acute
myeloid leukemia. Leukemia 2001; 15: 1072–1080. 3 Guerrasio A, Pilatrino C, De Micheli D …
prognostic significance of KIT mutations in adult acute myeloid leukemia with inv (16) and t
(8; 21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 3904–3911. 2
Marcucci G, Caligiuri MA, Dohner H, Archer KJ, Schlenk RF, Dohner K et al. Quantification of
CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV (16) acute
myeloid leukemia. Leukemia 2001; 15: 1072–1080. 3 Guerrasio A, Pilatrino C, De Micheli D …
1 Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv (16) and t (8; 21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 3904–3911. 2 Marcucci G, Caligiuri MA, Dohner H, Archer KJ, Schlenk RF, Dohner K et al. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV (16) acute myeloid leukemia. Leukemia 2001; 15: 1072–1080. 3 Guerrasio A, Pilatrino C, De Micheli D, Cilloni D, Serra A, Gottardi E et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 2002; 16: 1176–1181. 4 Perea G, Lasa A, Aventin A, Domingo A, Villamor N, Queipo de Llano MP et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t (8; 21) and inv (16)]. Leukemia 2006; 20: 87–94. 5 Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003; 102: 2746–2755. 6 Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of ‘real-time’quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemiaFa Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.
7 Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006; 20: 965–970. 8 Stentoft J, Hokland P, Ostergaard M, Hasle H, Nyvold CG. Minimal residual core binding factor AMLs by real time quantitative PCRFinitial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leuk Res 2006; 30: 389–395.
nature.com